hrcak mascot   Srce   HID

Pregledni rad
https://doi.org/10.20471/acc.2018.57.03.16

Thyroglobulin as a Tumor Marker in Differentiated Thyroid Cancer – Clinical Considerations

Marin Prpić ; Department of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia
Maja Franceschi ; Department of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia; Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
Matija Romić ; Department of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia
Tomislav Jukić ; Department of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia; Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
Zvonko Kusić ; Croatian Academy of Sciences and Arts, Zagreb, Croatia; Aviva Polyclinic, Zagreb, Croatia

Puni tekst: engleski, pdf (496 KB) str. 518-526 preuzimanja: 377* citiraj
APA 6th Edition
Prpić, M., Franceschi, M., Romić, M., Jukić, T. i Kusić, Z. (2018). Thyroglobulin as a Tumor Marker in Differentiated Thyroid Cancer – Clinical Considerations. Acta clinica Croatica, 57. (3.), 518-526. https://doi.org/10.20471/acc.2018.57.03.16
MLA 8th Edition
Prpić, Marin, et al. "Thyroglobulin as a Tumor Marker in Differentiated Thyroid Cancer – Clinical Considerations." Acta clinica Croatica, vol. 57., br. 3., 2018, str. 518-526. https://doi.org/10.20471/acc.2018.57.03.16. Citirano 29.07.2021.
Chicago 17th Edition
Prpić, Marin, Maja Franceschi, Matija Romić, Tomislav Jukić i Zvonko Kusić. "Thyroglobulin as a Tumor Marker in Differentiated Thyroid Cancer – Clinical Considerations." Acta clinica Croatica 57., br. 3. (2018): 518-526. https://doi.org/10.20471/acc.2018.57.03.16
Harvard
Prpić, M., et al. (2018). 'Thyroglobulin as a Tumor Marker in Differentiated Thyroid Cancer – Clinical Considerations', Acta clinica Croatica, 57.(3.), str. 518-526. https://doi.org/10.20471/acc.2018.57.03.16
Vancouver
Prpić M, Franceschi M, Romić M, Jukić T, Kusić Z. Thyroglobulin as a Tumor Marker in Differentiated Thyroid Cancer – Clinical Considerations. Acta clinica Croatica [Internet]. 2018 [pristupljeno 29.07.2021.];57.(3.):518-526. https://doi.org/10.20471/acc.2018.57.03.16
IEEE
M. Prpić, M. Franceschi, M. Romić, T. Jukić i Z. Kusić, "Thyroglobulin as a Tumor Marker in Differentiated Thyroid Cancer – Clinical Considerations", Acta clinica Croatica, vol.57., br. 3., str. 518-526, 2018. [Online]. https://doi.org/10.20471/acc.2018.57.03.16

Sažetak
Initial treatment of the majority of patients with differentiated thyroid cancer (DTC) includes total thyroidectomy. Postoperative ablation therapy with radioactive iodine (I-131) is indicated in all high-risk patients, however, there is disagreement regarding its use in low- and intermediate-risk patients. Over the last few decades, thyroglobulin (Tg) has been established as the primary biochemical tumor marker for patients with DTC. Thyroglobulin can be measured during thyroid hormone therapy or after thyroid-stimulating hormone (TSH) stimulation, through thyroid hormone withdrawal or the use of human recombinant TSH. In many studies, the cut-off value for adequate Tg stimulation is a TSH value ≥30 mIU/L. However, there is an emerging body of evidence suggesting that this long-established standard should be re-evaluated, bringing this threshold into question. Recently, a risk stratification system of response to initial therapy (with four categories) has been introduced and Tg measurement is one of the main components. The relationship between the Tg/TSH ratio and the outcome of radioiodine ablation has also been studied, as well as clinical significance of serum thyroglobulin doubling-time. The postoperative serum Tg value is an important prognostic factor that is used to guide clinical management, and it is the most valuable tool in long term follow-up of patients with DTC.

Ključne riječi
Thyroglobulin; Thyroid neoplasms; Thyroidectomy; Iodine radioisotopes; Biomarkers, tumor; Thyroid hormones; Croatia

Hrčak ID: 216159

URI
https://hrcak.srce.hr/216159

[hrvatski]

Posjeta: 999 *